Myo-inositol
Also called: inositol, myoinositol
Myo-inositol is one form of inositol sold as a dietary supplement, studied mainly in polycystic ovary syndrome (PCOS) and pregnancy. A related form, D-chiro-inositol, is sold separately or combined with it.
- Category
- Other
- Forms
- Myo-inositol powder or capsules; sometimes combined with D-chiro-inositol
- Strongest evidence
- B Some positive trials
- Reviewed
- 2026-10-28
Class 1 Well studied in people. A 2024 systematic review for the international PCOS guideline found 20 studies of myo-inositol (1-4 g/day, alone or with folic acid) versus metformin, folic acid or placebo; it pooled 10 RCTs of myo-inositol versus metformin. [3]
Fact-checked 2026-10-28 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
BPregnancy and infants2 topics
CBrain, mood and sleep1 topic
CHormones and reproduction1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Gestational diabetes and other pregnancy outcomes | B | A Cochrane review of 7 trials (1,319 pregnant women; 6 in Italy) found myo-inositol may reduce gestational diabetes (RR 0.53) and hypertensive disorders of pregnancy; certainty was low to very low. [1] |
| Live birth and pregnancy in subfertile women with PCOS | C | A Cochrane review of 13 trials (1,472 women, mostly before IVF) found very low-quality evidence; it is uncertain whether myo-inositol improves live birth or clinical pregnancy rates. [2] |
| Metabolic and hormonal measures in PCOS | C | A guideline meta-analysis of 30 trials (2,230 women) found possible benefits for some metabolic measures but likely no effect on other outcomes; evidence was limited and inconclusive. [3] |
| Depression and anxiety disorders | C | A meta-analysis of 7 depression trials (242 people) and 4 anxiety-disorder trials (70) found no significant effect on depressive, anxiety or obsessive-compulsive symptoms; a trend appeared in PMDD. [4] |
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingCochrane review (2023): seven RCTs in 1,319 pregnant women (six in Italy, one in Ireland).
1 statement in the profile.
Details and sources - Interactions with medicinesNothing found
No published information found in the sources checked.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- Myo-inositol likely causes fewer gastrointestinal side effects than metformin; these are typically mild and self-limited. [3]
- In a meta-analysis of psychiatric trials, inositol caused marginally more gastrointestinal upset than placebo (p = 0.06). [4]
- Pregnancy trials were small and not powered to detect differences in perinatal death or serious infant illness; reviewers called for study of potential harms. [1]
Regulatory status
- US: FDA states that, by law, it does not approve dietary supplements or their labeling before they are marketed; firms are responsible for the safety and labeling of their products. [5]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Myo-inositol Isomer of inositol; a naturally occurring sugar found in cereals, corn, legumes and meat [P1]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming myo-inositol was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). Three entries name "inositol" within a complex or combination without stating the isomer (NDI 308, 501, 786), and one names D-chiro-inositol from carob pods (NDI 1081, submitted 2018-07-09). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P3]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- No published information found in the sources checked.
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination of each component that is a dietary ingredient, before use — Required by 21 CFR 111.75(a)(1)(i); a manufacturer may petition for an exemption from this testing under 111.75(a)(1)(ii). [P6]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- Soft gelatin capsules of myo-inositol showed pharmacokinetic parameters similar to three-times-higher doses of myo-inositol powder (single-dose study, 20 healthy volunteers). [P2]
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- Cochrane review (2023): seven RCTs in 1,319 pregnant women (six in Italy, one in Ireland). The studies were small and not powered to detect differences in perinatal mortality and serious infant morbidity; the authors call for future trials to report potential harms, including adverse effects. [P1]
Sources for this profile
- Motuhifonua SK, et al. Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes. Cochrane Database Syst Rev 2023;2:CD011507 (PMID 36790138), 2023-02-15. pubmed.ncbi.nlm.nih.gov
- Carlomagno G, et al. Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use. Expert Opin Drug Deliv 2012;9(3):267-71 (PMID 22339497), 2012-03. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications (accessed October 29, 2026), 2026-10-29. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (TR) list (accessed October 29, 2026), 2026-10-29. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75 (title 21 displayed up to date as of 10/23/2026), 2026-10-23. ecfr.gov
Sources
- Motuhifonua SK, et al. Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes. Cochrane Database Syst Rev 2023;2:CD011507 (PMID 36790138), 2023-02-15. pubmed.ncbi.nlm.nih.gov
- Showell MG, et al. Inositol for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev 2018;12:CD012378 (PMID 30570133), 2018-12-20. pubmed.ncbi.nlm.nih.gov
- Fitz V, et al. Inositol for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 update of the International Evidence-based PCOS Guidelines. J Clin Endocrinol Metab 2024;109(6):1630-1655 (PMID 38163998), 2024-05-17. pubmed.ncbi.nlm.nih.gov
- Mukai T, et al. A meta-analysis of inositol for depression and anxiety disorders. Hum Psychopharmacol 2014;29(1):55-63 (PMID 24424706), 2014-01. pubmed.ncbi.nlm.nih.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in this category: Alpha-lipoic acid · Bee pollen · Beetroot juice (dietary nitrate) · Berberine · Beta-glucan (oat and barley) · Betaine (trimethylglycine) · Bromelain · Caffeine · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.